These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38743241)

  • 1. Early Therapeutic Drug Monitoring Optimizes Teicoplanin Use in Febrile Neutropenic Patients with Hematological Malignancies.
    Wang YW; Hou HA; Lin CC; Lin HY; Chen PZ; Kuo CH; Chiu HH; Chuang CC; Chen YJ; Lin SW
    Adv Ther; 2024 Jul; 41(7):2966-2977. PubMed ID: 38743241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal Trough Concentration of Teicoplanin in Febrile Neutropenic Patients with Hematological Malignancy.
    Sato Y; Hiramatsu K; Suzuki Y; Tanaka R; Kaneko T; Nonoshita K; Ogata M; Kadota JI; Itoh H
    Chemotherapy; 2018; 63(1):29-34. PubMed ID: 29169153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Drug Monitoring of Teicoplanin in Haematological Malignancy Patients with Febrile Neutropenia and Optimizing Dosage Regimens.
    Hu S; Wang T; You H; Wei S; Song H; Zhang T; Zhang D; Dong Y
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):594-601. PubMed ID: 29702731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal teicoplanin loading regimen to rapidly achieve target trough plasma concentration in critically ill patients.
    Li H; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Zhang Y; Wang T; Shi Q
    Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):277-288. PubMed ID: 31608579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days.
    Ueda T; Takesue Y; Nakajima K; Ichiki K; Ishikawa K; Takai Y; Yamada K; Tsuchida T; Otani N; Takahashi Y; Ishihara M; Takubo S; Ikeuchi H; Uchino M; Kimura T
    BMC Pharmacol Toxicol; 2020 Jul; 21(1):50. PubMed ID: 32641110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal trough concentration of teicoplanin for the treatment of methicillin-resistant Staphylococcus aureus infection: A systematic review and meta-analysis.
    Hanai Y; Takahashi Y; Niwa T; Mayumi T; Hamada Y; Kimura T; Matsumoto K; Fujii S; Takesue Y
    J Clin Pharm Ther; 2021 Jun; 46(3):622-632. PubMed ID: 33547647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy.
    Kim SH; Kang CI; Huh K; Cho SY; Chung DR; Lee SY; Kim YJ; Peck KR
    Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2113-2120. PubMed ID: 31372903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages.
    Pea F; Viale P; Candoni A; Pavan F; Pagani L; Damiani D; Casini M; Furlanut M
    Clin Pharmacokinet; 2004; 43(6):405-15. PubMed ID: 15086277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy.
    Byrne CJ; Roberts JA; McWhinney B; Ryder SA; Fennell JP; O'Byrne P; Deasy E; Egan S; Desmond R; Enright H; D'Arcy DM; McHugh J
    Clin Microbiol Infect; 2017 Sep; 23(9):674.e7-674.e13. PubMed ID: 28267636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variability in Trough Total and Unbound Teicoplanin Concentrations and Achievement of Therapeutic Drug Monitoring Targets in Adult Patients with Hematological Malignancy.
    Byrne CJ; Roberts JA; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Desmond R; Enright H; Ryder SA; D'Arcy DM; McHugh J
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction.
    Ueda T; Takesue Y; Nakajima K; Ichiki K; Doita A; Wada Y; Tsuchida T; Takahashi Y; Ishihara M; Ikeuchi H; Uchino M; Kimura T
    Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1501-9. PubMed ID: 27278654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen.
    Cazaubon Y; Venisse N; Mimoz O; Maire P; Ducher M; Bourguignon L; Goutelle S
    J Antimicrob Chemother; 2017 Oct; 72(10):2804-2812. PubMed ID: 29091222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teicoplanin use in adult patients with haematological malignancy: Exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity.
    Byrne CJ; Egan S; Fennell JP; O'Byrne P; Enright H; Deasy E; Ryder SA; D'Arcy DM; McHugh J
    Int J Antimicrob Agents; 2015 Oct; 46(4):406-12. PubMed ID: 26228465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective analysis to estimate target trough concentration of vancomycin for febrile neutropenia in patients with hematological malignancy.
    Suzuki Y; Tokimatsu I; Morinaga Y; Sato Y; Takano K; Kohno K; Ogata M; Hiramatsu K; Itoh H; Kadota J
    Clin Chim Acta; 2015 Feb; 440():183-7. PubMed ID: 25476135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program.
    Menichetti F; Martino P; Bucaneve G; Gentile G; D'Antonio D; Liso V; Ricci P; Nosari AM; Buelli M; Carotenuto M
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2041-6. PubMed ID: 7811016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of Therapeutic Drug Monitoring of Teicoplanin at the Onset of Febrile Neutropenia.
    Takigawa M; Tanaka H; Suwa J; Obara T; Maeda Y; Sato M; Shimazaki Y; Onoda T; Ishigami A; Ishii T
    Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109716
    [No Abstract]   [Full Text] [Related]  

  • 17. Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infections.
    Wang JT; Liao HI; Wu Lin FL; Chang SC
    Basic Clin Pharmacol Toxicol; 2012 May; 110(5):416-20. PubMed ID: 22309355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose.
    Pea F; Brollo L; Viale P; Pavan F; Furlanut M
    J Antimicrob Chemother; 2003 Apr; 51(4):971-5. PubMed ID: 12654757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate-severe Gram-positive infections.
    Zhou L; Gao Y; Cao W; Liu J; Guan H; Zhang H; Shi Y; Lv W; Cheng L
    Infect Drug Resist; 2018; 11():29-36. PubMed ID: 29379306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
    Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
    Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.